Renovos Biologics
Renovos is a pioneering company based in Southampton, UK, specializing in advanced nanoclay platform technology for regenerative medicine. Their mission is to develop safer, more effective, and cost-efficient tissue regeneration solutions using their proprietary RENOVITE® nanoclay platform, which acts as an injectable scaffold to localize and retain biologics, promoting tissue repair across various applications. Supported by decades of academic research, Renovos aims to transform patient lives by enabling safer and more precise regenerative treatments, with a focus on orthobiologics, bone and cartilage repair, dental, and skin applications.
Industries
Nr. of Employees
small (1-50)
Renovos Biologics
University of Southampton Science Park, 2 Venture Road, Chilworth, Southampton, SO16 7NP, UK
Patents
Products
Synthetic nanoclay-based injectable therapeutic delivery platform
An injectable nanoclay gel scaffold designed to localise and retain therapeutic molecules and host regenerative cells, engineered for biocompatibility and gradual resorption during tissue repair.
Nanoclay carrier formulation for BMP-2 delivery (orthobiologic application)
A carrier formulation that localises BMP-2 at the implant site to improve bone fusion quality and reduce off-target diffusion and adverse effects compared with conventional carriers.
Human bone marrow-derived mesenchymal stem cell preparations for research
Research-grade MSC products sourced and provided with donor metadata (age, disease-state), available at multiple purity levels (unselected, enriched, clonal) and low passage for biologics and biomaterial testing.
Synthetic nanoclay-based injectable therapeutic delivery platform
An injectable nanoclay gel scaffold designed to localise and retain therapeutic molecules and host regenerative cells, engineered for biocompatibility and gradual resorption during tissue repair.
Nanoclay carrier formulation for BMP-2 delivery (orthobiologic application)
A carrier formulation that localises BMP-2 at the implant site to improve bone fusion quality and reduce off-target diffusion and adverse effects compared with conventional carriers.
Human bone marrow-derived mesenchymal stem cell preparations for research
Research-grade MSC products sourced and provided with donor metadata (age, disease-state), available at multiple purity levels (unselected, enriched, clonal) and low passage for biologics and biomaterial testing.
Services
Collaborative or licensing arrangements to integrate the synthetic nanoclay delivery platform into third-party therapeutics, biologics, or device development programmes.
Collaborative development support including formulation optimisation, preclinical testing, and publication-backed validation work to advance candidates toward clinical evaluation.
Collaborative or licensing arrangements to integrate the synthetic nanoclay delivery platform into third-party therapeutics, biologics, or device development programmes.
Collaborative development support including formulation optimisation, preclinical testing, and publication-backed validation work to advance candidates toward clinical evaluation.
Expertise Areas
- Regenerative medicine and orthobiologics
- Biomaterials development (nanoclay-based)
- Localized drug/biologics delivery
- Stem cell sourcing and research-grade MSCs
Key Technologies
- Synthetic nanoclay gel scaffolds
- Hydrogel self-assembly via nanoparticle–polymer interactions
- Localized sustained growth-factor delivery
- Injectable narrow-gauge-compatible formulations
News & Updates
Renovos has achieved several milestones and successes over 2024, including expanding their technical team and advancing their nanoclay technology platform.
Professor Richard Oreffo, CSO of Renovos, received the 2024 Biomaterials Advances Innovation Award for his innovative research in biomaterials.
Richard Oreffo was appointed an Officer of the Order of the British Empire in the King’s New Year’s Honours for his services to education, equality, and musculoskeletal science.
Renovos was recognized at RESI London 2024 for their innovative regenerative medicine platform.
Renovos showcased their nanoclay platform at VentureFest South and received recognition for their innovation.
Lisa Ferrara, with over 30 years of experience in orthopaedic medical device innovation, joins Renovos' board to strengthen US expertise.
Renovos has achieved several milestones and successes over 2024, including expanding their technical team and advancing their nanoclay technology platform.
Professor Richard Oreffo, CSO of Renovos, received the 2024 Biomaterials Advances Innovation Award for his innovative research in biomaterials.
Richard Oreffo was appointed an Officer of the Order of the British Empire in the King’s New Year’s Honours for his services to education, equality, and musculoskeletal science.
Renovos was recognized at RESI London 2024 for their innovative regenerative medicine platform.
Renovos showcased their nanoclay platform at VentureFest South and received recognition for their innovation.
Lisa Ferrara, with over 30 years of experience in orthopaedic medical device innovation, joins Renovos' board to strengthen US expertise.